The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias
Open accessAbstract
The management of dementia has changed since the development of new antidementia drugs. The benefits observed in Alzheimer's disease (AD) with selective cholinergic transmission treatments are mainly symptomatic, without clear evidence of neuroprotection. The hypothesis that glutamate-mediated neurotoxicity is involved in the pathogenesis of AD is finding increasingly more acceptance in the scientific community. Glutamate receptors are overactive, and N-methyl-D-aspartate (NMDA) receptor antagonists have therapeutic potential for the treatment of AD and other neurological disorders. Memantine is a noncompetitive NMDA antagonist that is considered a neuroprotective drug. Memantine's capacity has been demonstrated in preclinical studies, and it is considered a useful symptomatic treatment for AD. Memantine has been shown to benefit cognition, function, and global outcome in patients with moderate to severe AD, and it is currently approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe AD. Recently, memantine has also demonstrated efficacy in the initial stages of AD, although FDA authorization is pending. This review highlights the important pharmacological and clinical aspects of memantine, as well as some basic mechanisms mediating glutamatergic neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dizziness, agitation, hallucinations, headache, and exhaustion were the most common symptoms that arose in clinical trials.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Molinuevo et al., 2005
In the citing paper
“Memantine (a glutamate receptor antagonist) is a promising drug molecule that inhibits excess glutamate activity, which is important for memory and learning.99”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Excitotoxity and the NMDA receptor
Rothman, S. M., & Olney, J. W. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90177-9 · Cited by 1,052
The Biochemistry of Memory: A New and Specific Hypothesis
LYNCH, G. S., & Baudry, M. (1984) · Science · doi:10.1126/science.6144182 · Cited by 1,041
The question of familial meningiomas and schwannomas:
King, A. A., & Gutmann, D. H. (2000) · Neurology · doi:10.1212/wnl.54.1.4 · Cited by 815
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Excitotoxicity and the NMDA receptor -- still lethal after eight years
Rothman, S. M. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93869-y · Cited by 508
Glutamate in CNS disorders as a target for drug development: an update
Parsons, C. G., Danysz, W., & Quack, G. (1998) · Drug News & Perspectives · doi:10.1358/dnp.1998.11.9.863689 · Cited by 438
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Treatment of Alzheimer's Disease
Mayeux, R. P., & Sano, M. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412207 · Cited by 393
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381
LI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343
Memory systems in the brain and localization of a memory
Thompson, R. F., & Kim, J. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13438 · Cited by 300
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265
Danysz, W., Parsons, C. G., Möbius, H. J., Stöffler, A., & Quack, G. (2000) · Neurotoxicity Research · doi:10.1007/bf03033787 · Cited by 262
Long-term potentiation : a debate of current issues
Baudry, M., & Davis, J. L. (1991) · Cited by 216
Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease
Minkeviciene, R., Banerjee, P., & Tanila, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071027 · Cited by 187
Kornhuber, J., & Quack, G. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11785-u · Cited by 155
Li, L., Sengupta, A., Haque, N., Grundke, I., & Iqbal, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.047 · Cited by 154
Caspase Dependent DNA Fragmentation Might Be Associated with Excitotoxicity in Alzheimer Disease
Masliah, E., Mallory, M. E., Alford, M. F., Tanaka, S., & Hansen, L. A. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199811000-00007 · Cited by 151
Barnes, C. A., Danysz, W., & Parsons, C. G. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01241.x · Cited by 149
Sze, C., Bi, H., Kleinschmidt-DeMasters, B. K., Filley, C. M., & Martin, L. J. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00467-6 · Cited by 146
β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus
Wu, J., Anwyl, R., & Rowan, M. J. (1995) · Neuroreport · doi:10.1097/00001756-199511270-00031 · Cited by 128
Görtelmeyer, R., & Erbler, H. C. (1992) · PubMed · Cited by 122
Evaluation of memantine for neuroprotection in dementia
Jain, K. K. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1397 · Cited by 111
Frankiewicz, T., & Parsons, C. G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00060-x · Cited by 110
Arias, C., Arrieta, I., & Tapia, R. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490410416 · Cited by 96
Müller, W. E. G., Mutschler, E., & Riederer, P. F. (1995) · Pharmacopsychiatry · doi:10.1055/s-2007-979603 · Cited by 90
Delayed administration of memantine prevents N‐methyl‐ D ‐aspartate receptor‐mediated neurotoxicity
Pellegrini, J. W., & Lipton, S. A. (1993) · Annals of Neurology · doi:10.1002/ana.410330414 · Cited by 89
Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B
Wenk, G. L., Zajaczkowski, W., & Danysz, W. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)86056-1 · Cited by 78
Synaptic plasticity: molecular, cellular, and functional aspects
(1994) · Choice Reviews Online · doi:10.5860/choice.31-6036 · Cited by 65
Effects of Pharmacologically Induced Changes in NMDA-Receptor Activity on Long-Term Memory in HumansPreprint
Rammsayer, T. H. (2001) · Learning & Memory · doi:10.1101/lm.33701 · Cited by 54
Memantine in Vascular Dementia
Möbius, H. J., & Stöffle, A. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009219 · Cited by 43
Memantine enhances autonomy in moderate to severe Alzheimer's disease
Rive, B., Vercelletto, M., Delamarre-Damier, F., Cochran, J. M., & François, C. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1112 · Cited by 40
Launer, L. J., & Hofman, A. (2000) · PubMed · Cited by 36
Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?
Winblad, B. G., Möbius, H. J., & Stöffler, A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_20 · Cited by 33
Möbius, H. J. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199912001-00024 · Cited by 31
AHMED, M., Hoshino, H., Chikuma, T., Yamada, M., & Kato, T. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.024 · Cited by 29
Couratier, P., Sindou, P., Tabaraud, F., Diop, A. G., Spencer, P. S., & Hugon, J. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0004 · Cited by 16
Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors
Berger, W., Deckert, J., Hartmann, J., Krotzer, C., Kornhuber, J., Ransmayr, G. N., Heinsen, H., Beckmann, H., & Riederer, P. F. (1994) · Neuroreport · doi:10.1097/00001756-199406020-00020 · Cited by 16
Synaptic plasticity: Molecular, cellular, and functional aspects
Holmes, G. L. (1994) · Journal of Epilepsy · doi:10.1016/0896-6974(94)90103-1 · Cited by 15
Kilpatrick, G. J., & Tilbrook, G. S. (2002) · PubMed · Cited by 10
Tanila, H., Minkeviciene, R., & Banerjee, P. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92211-5 · Cited by 7
Pomara, N., Peskind, E. R., Potkin, S. G., McDonald, S., Xie, Y., & Gergel, I. P. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80063-0 · Cited by 7
Iqbal, K., Li, L., Sengupta, A., & Grundke, I. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92213-9 · Cited by 6
Potkin, S. G., McDonald, S., Gergel, I. P., Alva, G., Keator, D. B., & Fallon, J. H. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)81254-5 · Cited by 5
P.4.012 Effect of memantine on levels of the amyloid beta peptide in cell cultures
Lahiri, D. K., Alley, G. M., Morgan, C., Banerjee, P., & Farlow, M. R. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92207-3 · Cited by 4
P1-021 Memantine treatment for mild to severe Alzheimer's disease: clinical trials summary
Tariot, P. N., Doody, R. S., Peskind, E. R., Winblad, B. G., Stöffler, A., Graham, S. M., & McDonald, S. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80335-x · Cited by 4
P.4.030 Pharmacokinetic study of memantine and donepezil in healthy young subjects
Periclou, A. P., Ventura, D., Sherman, T., Rao, N. S., Mengel, H. B., & Abramowitz, W. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92224-3 · Cited by 3
P1-343 Memantine is safe for short- and long-term treatment of dementia
Graham, S. M., Jonas, J. M., Lee, G. S., Goetz, M. A., Stöffler, A., & Wirth, Y. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80656-0 · Cited by 2
P3-210 Memantine prevents Aβ1–40-induced apoptotic cell death in the rat hippocampus
Miguel-Hidalgo, J. J., Paul, I. A., Wanzo, V., & Banerjee, P. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)81360-5 · Cited by 1
Lahiri, D. K., Bailey, J. A., Alley, G. M., Chen, D., Sambamurti, K., & Greig, N. H. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80214-8 · Cited by 1
P1-315 Functional and behavioral effects of memantine in Alzheimer's disease
Cummings, J. L., van Dyck, C. H., Schmitt, F. A., Graham, S. M., Olin, J. T., Jin, J., & Tariot, P. N. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80628-6 · Cited by 1
Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Research works printed but not linked: 7
- Lobo A, 2000, Neurology, 54, S4
- Launer LJ, 2000, Neurology, 54, S1
- Kilpatrick GJ, 2002, Curr Opin Investig Drugs, 3, 798
- Danysz W, 1995, Drug News Perspect, 8, 261
- Landfield PW, 1988, Long-Term Potentiation: A Debate of Current Issues
- Pantev M, 1993, Zeitschrift Gentopsychol Psychiatrie, 6, 103
- Reisberg B, 2003, Eur Neuropsychopharmacol, 13, S388
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Calcium Signaling and Amyloid Toxicity in Alzheimer Disease
Demuro, A., Parker, I., & Stutzmann, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.080895 · Cited by 426
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 320
Blaylock, R. L., & Maroon, J. C. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.83391 · Cited by 212
The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Metadata
- Authors
- Molinuevo, J. L., Lladó, A., & Rami, L.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2005-03
- Volume
- 20
- Issue
- 2
- Pages
- 77-85
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- PMC
- PMC10833270
- OpenAlex
- W2140959932
- Cited by
- 125
- References
- 58
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 2 · 2015: 8 · 2014: 5 · 2013: 8 · 2012: 4
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- memantine, Alzheimer's disease, dementia, glutamate excitotoxicity, NMDA receptor antagonists, neuroprotection, symptomatic treatment, clinical efficacy
- MeSH terms
- Animals, Clinical Trials as Topic, Dementia, Drug Evaluation, Preclinical, Humans, Memantine, Molecular Structure, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Glutamic Acid, Amino Acid Transport System X-AG
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
